| __timestamp | Halozyme Therapeutics, Inc. | Jazz Pharmaceuticals plc |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 406114000 |
| Thursday, January 1, 2015 | 40028000 | 449119000 |
| Friday, January 1, 2016 | 45853000 | 502892000 |
| Sunday, January 1, 2017 | 53816000 | 544156000 |
| Monday, January 1, 2018 | 60804000 | 683530000 |
| Tuesday, January 1, 2019 | 77252000 | 736942000 |
| Wednesday, January 1, 2020 | 45736000 | 854233000 |
| Friday, January 1, 2021 | 50323000 | 1451683000 |
| Saturday, January 1, 2022 | 143526000 | 1416967000 |
| Sunday, January 1, 2023 | 149182000 | 1343105000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, understanding financial trends is crucial. Over the past decade, Jazz Pharmaceuticals and Halozyme Therapeutics have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Jazz Pharmaceuticals, with a consistent upward trend, saw its SG&A expenses grow by approximately 230% from 2014 to 2023, peaking in 2021. This reflects their aggressive expansion and marketing strategies. In contrast, Halozyme Therapeutics experienced a more volatile pattern, with a notable spike in 2022, marking a 315% increase since 2014. This surge could indicate strategic shifts or increased operational costs. These trends highlight the differing strategic priorities and market responses of these two industry players. As the pharmaceutical sector continues to evolve, monitoring such financial indicators provides valuable insights into company performance and market positioning.
Who Optimizes SG&A Costs Better? Alnylam Pharmaceuticals, Inc. or Jazz Pharmaceuticals plc
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs Jazz Pharmaceuticals plc
BioMarin Pharmaceutical Inc. and Jazz Pharmaceuticals plc: SG&A Spending Patterns Compared
Annual Revenue Comparison: Jazz Pharmaceuticals plc vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Halozyme Therapeutics, Inc.'s Expenses
Breaking Down SG&A Expenses: Jazz Pharmaceuticals plc vs Alpine Immune Sciences, Inc.
Jazz Pharmaceuticals plc vs Xencor, Inc.: SG&A Expense Trends
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.